LBS 4 and LBS 5 EMBARGOED Media Briefing 7:30-8:30 am CT, Sunday, Nov. 15, 2020.

[LBS 4 and 5 Briefing Speakers](https://newsroom.heart.org/_gallery/get_file/?file_id=5facb9802cfac21602b2c1ce&file_ext=.docx&page_id=) (doc)

MICHAEL LINCOFF – STRENGTH

ON BEHALF OF THE INVESTIGATORS IT IS MY PLEASURE TO REPORT THE RESULTS OF THIS TRIAL. MY DISCLOSURES ARE ON THE SLIDE. SO, THIS REMAINS COMPLETELY UNDEFINED. OMEGA-3 OXALIC ACID IS A COMPOUND THAT DOES NOT REQUIRE LIGHT ABSORPTION AND ENHANCES BY ABILITY TO ACHIEVE HIGHER BLOOD LEVELS REGARDLESS OF CO- INGESTION OF FATTY MEALS. THE CARDIOVASCULAR OUTCOME TRIAL COMPARED A HIGH DOSE OF OMEGA-3 CARBOXYLIC ACID WHICH IS A COMBINATION OF EPA AND DJ. THERE IS A CORNER PLACEBO. CORA NORM WAS CHOSEN AS THE PLACEBO IN THIS TRIAL. IT HAS A NEUTRAL AFFECT ON CHEMICAL PARAMETERS WHEREAS -- OLIVE OIL IS LIKELY A POSITIVE CONTROL. MINERAL OIL IS A NEGATIVE CONTROL. WE ENROLLED PATIENTS WHO WERE TREATED AT HIGH RISK OR HAD CARDIOVASCULAR DISEASE AND HAD HIGH TRIGLYCERIDES FROM LOW HDL. THE PRIMARY EFFICACY. WAS THE CARDIOVASCULAR DEATH -- STROKE , HOSPITALIZATION --THIS WAS THE MAIN POINT. IT REQUIRED 1600 EVENTS TO HAVE A REDUCTION -- WE RANDOMIZED BETWEEN OCTOBER 2014 AND JUNE OF 2017 FOR 78 PATIENTS. IN JANUARY OF 2020, THE DATA SAFETY MONITORING ACTIVITY RECOMMENDED TERMINATION OF THE TRIAL BASED ON FUTILITY DURING A PLANNED ANALYSIS. WE STOPPED THE STUDY DRUG . BY MAY, 1500 POINTS HAVE BEEN ACCRUED. DESPITE THE COVERT EPIDEMIC, WE WERE ABLE TO ACHIEVE THIS STATUS -- IN 96% OF PATIENTS -- 38.4 MONTHS. THE BIOCHEMICAL PARAMETERS REFLECTED THE EFFECT OF THE DRUG. IT WAS REDUCED BY 19%. LDL HDL -- THE MARKER OF INFORMATION WAS REDUCED BY 20%. PLASMA AND RED BLOOD CELLS WERE INCREASED BETWEEN 270 OR 300%. THERE WERE MORE MODEST INCREASES -- DESPITE BIOCHEMICAL EFFECTS, THERE WAS NO DIFFERENCE IN THE OUTCOME WITH TREATMENT OF OMEGA-3 CARBOXYLIC ACID. THERE WERE NO DIFFERENCES IN THE COMPONENTS OF THE MORTALITY. THE MAJOR ADVERSE AFFECT OF THE CONCERN WAS ATRIAL FIBRILLATION WHICH WAS INCREASED BY 70% WITH THE EVENTS OVER THE ENTIRE FOLLOW-UP PERIOD. OTHER ADVERSE EFFECTS WERE PRETTY MUCH CONFINED TOO GASTROINTESTINAL --IT HAD CONTINUATION AS A RESULT. SO, HOW THEN DO WE RECONCILE THE RESULTS OF THE STRENGTH TRIAL SHOWING A NEUTRAL AFFECT OF THE OMEGA-3 CARBOXYLIC ACID WITH THE REDUCE IN TRIAL SHOWING A FAVORABLE EFFECT OF THE EPA COMPOUND. CLEARLY, ANY TYPE OF --WOULD BE SPECULATIVE AT THIS POINT. IT IS IMPORTANT TO --THE DIFFERENCE BEEN HIGH LEVELS OF EPA ? IF YOU REDUCE IT, THE INCREASE IN EPA FROM BASELINE TO 12 MONTHS WAS APPROXIMATELY 45% GREATER OF THE ACHIEVEMENT FROM THE CARBOXYLIC ACID IN THE STRENGTH TRIAL. THIS SEEMS INSUFFICIENT TO EXPLAIN THE RESULTS OF THE TWO TRIALS. MOREOVER, WHEN WE EXAMINE THE RELATIONSHIP BETWEEN THE LEVELS IN OUR TRIAL, IN BOTH TRIALS, THERE WAS A TRIGLYCERIDES ADJUSTING CHEMICAL EFFECTS. OUR DRUG IS A COMBINATION OF EPA AND DHA. POSSIBLY, THE DHA HAD A TOXIC EFFECT WHICH NEUTRALIZE THE EPA AFFECT. IT HAS NEVER BEEN ASSOCIATED WITH INCREASED RISK OR ADVERSE CARDIOVASCULAR --ADVERSE EFFECTS IN PRECLINICAL MODELS. DHA LEVELS HIGHLY CORRELATE WITH --THERE WERE DIFFERENCES IN THE TRIAL POPULATION, THE TRIAL HAD MORE PATIENTS WITH ESTABLISHED DISEASE. THERE WERE NO AFFECTS EVEN IN THE HIGHER RISK GROUP OF PATIENTS. SO, WE NEED TO CONSIDER THE POSSIBILITY THAT SOME OF THE DIFFERENCES --WE HAD AN EFFECT ON --MINERAL OIL HAS BEEN SHOWN TO HAVE AN ADVERSE EFFECT ON LIPIDS AND INFLAMMATORY MARKERS. IN OUR TRIAL, THERE WERE NO DIFFERENCE IN THESE PARAMETERS. INDUCE A TRIAL WITH MINIMAL -- MINERAL OIL, THERE WERE UNFAVORABLE INCREASES. EVEN A TIGHT CONNECTION BETWEEN THESE BIOMARKERS AND INCREASED CARDIOVASCULAR RISK, WE HAVE TO SEE THAT SOME OF THE DIFFERENCES BETWEEN THE TRIALS AND SOME OF THE EFFICACY REDUCED MIGHT HAVE BEEN DUE TO INCREASE IN THE PLACEBO CONTROL GROUP WITH MINERAL OIL. TO CONCLUDE, ADMINISTRATION OF OMEGA-3 CARBOXYLIC ACID AT A HIGH DOSE DID NOT REDUCE THE INCIDENCE OF MAJOR CARDIOVASCULAR EVENTS. DESPITE A 300% INCREASE, THE CORN OIL CONFUSED WITH MINERAL OIL HAD NO EFFECT , SUGGESTING IT WAS A TRULY NEUTRAL COMPARATIVE. GIVEN THESE FINDINGS IN THE CONTEXT OF THE ATRIAL FIBRILLATION IN THIS AND OTHER TRIALS OF OMEGA-3 FATTY ACIDS CASTS A QUESTION REGARDING WHETHER OR NOT THERE IS A NET BENEFIT OR HARM WITH OMEGA-3 FATTY ACID --THANK YOU VERY MUCH.